Repeated anti-CEA-radioimmunotherapy (RAIT) with 131iodine-labetuzumab after resection of colorectal liver metastases (CLM): a prospective phase II study.

Trial Profile

Repeated anti-CEA-radioimmunotherapy (RAIT) with 131iodine-labetuzumab after resection of colorectal liver metastases (CLM): a prospective phase II study.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2015

At a glance

  • Drugs Labetuzumab I 131 (Primary)
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Sponsors Immunomedics
  • Most Recent Events

    • 25 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top